Acorda's multiple sclerosis drug faces generic threat

Send a link to a friend  Share

[June 26, 2014] (Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.

Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.

Acorda said Actavis has submitted a marketing approval application with the U.S. Food and Drug Administration for a generic version of the drug.

Acorda said it intends to vigorously defend its intellectual property rights.

(Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)
 

[to top of second column]

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top